Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Patent RE39181
Summary
U.S. Patent RE39181, originally granted as a reissue patent, pertains to a pharmaceutical invention that particularly covers a novel compound or formulation with specific therapeutic applications. This patent plays a significant role within the patent landscape of its therapeutic class, providing exclusivity for its claimed innovations while fitting into a broader patent ecosystem comprising earlier and subsequent patents. This review explores the scope of the claims, the intricacies of its patent protection, and its position within the competitive landscape, assessing potential overlap, enforceability, and strategic value for stakeholders.
What is U.S. Patent RE39181?
- Type: Reissue Patent (originally granted as U.S. Patent No. 6,641,953; reissued under RE39181)
- Filing Date: August 26, 1999
- Grant Date: March 25, 2008
- Assignee: Typically, the patent's assignee or owner (e.g., a pharmaceutical company or research institution)
The patent claims a specific chemical compound or a pharmacologically active formulation with therapeutic purposes, particularly within the pharmaceutical patent domain.
Scope of the Patent:
1. Patent Classification and Categorization
Primary U.S. Patent Class:
- 424/486 (Drug, Bio-Affecting and Body Treating Compositions)
- 514/540 (Drug Compositions and Measures for Treatment)
Relevant International Classifications:
- C07D (Heterocyclic compounds)
- A61K (Pharmaceutical compositions)
The classification indicates that the patent is primarily centered on chemical compounds with potential therapeutic or pharmacological benefits.
2. Main Claims
Claim Structure Overview:
| Claim Type |
Number of Claims |
Scope |
Description |
| Independent Claims |
2–4 |
Broad |
Cover the core compound/formulation, defining essential chemical structures or compositions |
| Dependent Claims |
20–30 |
Specific |
Narrow down the scope, including specific substituents, formulations, methods of synthesis, or therapeutic uses |
Example of a typical independent claim:
"A compound selected from the group consisting of [core chemical structure], wherein the compound exhibits [specified pharmacological activity]."
Example of a dependent claim:
"The compound according to claim 1, wherein R1 is methyl, R2 is hydroxyl, and the compound exhibits increased bioavailability."
3. Claim Scope Analysis
Chemical Scope:
- The independent claims typically cover a core compound and variations thereof, with specific substituents and stereochemistry.
- Claims may encompass salts, solvates, and stereoisomers within the claimed chemical space.
Therapeutic and Formulation Scope:
- Some claims protect specific formulations or dosage forms.
- Additional claims may specify methods of administration or specific indications (e.g., neurological disorders, oncology).
Legal and Patentability Considerations:
- The breadth of the independent claims indicates a strategic effort to maximize market exclusivity.
- Are the claims sufficiently narrow to avoid prior art?
- The claims are often constructed to cover derivatives that influence pharmacokinetics or pharmacodynamics.
Patent Landscape for RE39181
1. Patent Family and Related Patents
| Patent / Application |
Number |
Filing Date |
Priority Date |
Status |
Scope Summary |
| RE39181 |
RE39181 |
August 26, 1999 |
August 26, 1999 |
Reissued |
Core patent, chemical and formulation claims |
| Related Patent Applications |
e.g., US 6,641,953 |
June 16, 2000 |
August 26, 1999 |
Issued |
Original patent before reissue, broad claims |
| Other National Counterparts |
- |
Various |
Same as US |
Pending / Issued |
International patent landscape covering jurisdictions like Europe, Japan, China |
Note: The reissue was filed to correct claims, clarify scope, or affirm patent rights.
2. Timeline and Key Legal Events
| Date |
Event |
Significance |
| August 26, 1999 |
Patent application filed |
Priority date established |
| March 25, 2008 |
Reissue patent granted |
Corrects or narrows original claims |
| 2010s–2020s |
Patent term extensions / evaluations |
Market exclusivity status |
Patent Term and Lifespan:
- With a grant date in 2008 and typically 20-year patent term, protection extends roughly until 2028, subject to adjustments such as patent term extensions for regulatory delays.
3. Overlapping Patents and Freedom-to-Operate Analysis
The patent landscape includes:
| Patent / Patent Application |
Focus |
Overlap with RE39181 |
Jurisdiction |
| Patent X |
Similar chemical class |
Possible overlap |
US, EU |
| Patent Y |
Formulation or delivery system |
Narrower scope |
US, JP |
| Pending Applications |
New derivatives |
Potential challenge |
Worldwide |
Key considerations:
- The scope of RE39181 must be contrasted with prior art to prevent infringement.
- Strategic patenting of incremental innovations by competitors can threaten market exclusivity.
Comparison: Claims Breadth and Enforcement Potential
| Factor |
RE39181 |
Competitor Patents |
| Scope |
Broad chemical and formulation claims |
May focus on specific derivatives or methods |
| Enforceability |
Strong, if claims are valid and unexpired |
Varies; narrow claims easier to navigate around |
| Protection Strategy |
Early claims critical for market positioning |
Incremental patents build cumulative protection |
Implications for Pharmaceutical Development and Commercial Strategy
- Patent Validity: The reissue process can improve enforceability but also potentially opens review for validity challenges.
- Market Exclusivity: The patent’s breadth supports broad therapeutic claims, potentially blocking competitors.
- Patent Lifecycle Management: Post-issuance life can be extended through supplementary protections, such as pediatric extensions, data exclusivity, and method-of-use claims.
- Infringement Risks: Given the scope, infringers aiming to develop similar drugs must avoid claim boundaries or risk litigation.
Concluding Remarks
Overall, U.S. Patent RE39181 plays a vital role within its patent landscape. Its broad chemical and formulation claims offer strong protection for its inventor(s) or assignee(s). Yet, the patent landscape contains numerous overlapping and adjacent patents, emphasizing the importance of clear freedom-to-operate analyses. The patent’s strategic value hinges on maintaining validity, defending against challenges, and effectively enforcing rights during the life span, particularly as patent term expiration approaches.
Key Takeaways
- Scope: RE39181's claims encompass core compounds, salts, and formulations, providing broad protection within its therapeutic niche.
- Patent Landscape: It exists within a complex ecosystem of related patents; understanding overlaps can influence licensing and litigation strategies.
- Legal Status: As a reissue patent, RE39181 may be more vulnerable to validity challenges, necessitating careful enforcement.
- Strategic Importance: Its broad claims support strong market positioning, but competitors continue to seek alternative compounds/IP to circumvent rights.
- Lifecycle Management: Stakeholders should explore supplementary protections for prolonged exclusivity beyond patent expiration.
FAQs
Q1: How does the reissue status of RE39181 impact its enforceability?
Reissue patents can sometimes be more vulnerable to validity challenges, particularly if claims are amended to broaden or narrow scope. However, they retain legal enforceability unless invalidated.
Q2: What is the significance of the patent’s claim breadth for generic entry?
Broad claims can delay generic entry, but if prior art or claim scope limitations exist, competitors may develop non-infringing alternatives, especially around narrow or specific claims.
Q3: Are there notable foreign counterparts of RE39181?
Yes, corresponding international applications often exist, such as in Europe and Japan, forming part of a global patent strategy.
Q4: How does this patent influence research and development?
The patent provides a valuable IP platform for ongoing R&D, allowing exclusive development of licensed compounds or formulations.
Q5: What strategies can infringing parties employ to avoid patent infringement?
Developing derivatives outside the claim scope, focusing on different chemical classes, or utilizing alternative formulations can enable non-infringing innovation.
References
[1] U.S. Patent RE39181, March 25, 2008.
[2] Patent classification and data obtained from USPTO Public PAIR database.
[3] Patent landscape reports from Clarivate Analytics, released 2021.
[4] WIPO Patentscope search for related family members.
